Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Public ClinicalTrials.gov record NCT04669899. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
JTX-8064-101 is a Phase 1/2, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose (RP2D) of JTX-8064 alone and in combination with a PD-1 inhibitor (PD-1i).
Study identification
- NCT ID
- NCT04669899
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 190 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2021 (Actual)
- Primary completion
- Nov 28, 2023 (Actual)
- Completion
- Nov 28, 2023 (Actual)
- Last update posted
- Apr 9, 2024
2021 – 2023
United States locations
- U.S. sites
- 45
- U.S. states
- 23
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Arizona Clinical Research Center | Tucson | Arizona | 85258 | — |
| University of Arkansas Medical Sciences | Little Rock | Arkansas | 72205 | — |
| City of Hope | Duarte | California | 91010 | — |
| California Cancer Associates for Research & Excellence, Inc. | La Jolla | California | 92037 | — |
| University of California, San Diego | La Jolla | California | 92093 | — |
| Cedars Sinai | Los Angeles | California | 90048 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| University of California, Davis | Sacramento | California | 95817 | — |
| Yale University | New Haven | Connecticut | 06519 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20057 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| University of Miami - Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Adventist Health System/Sunbelt, Inc. | Orlando | Florida | 32803 | — |
| Tampa General Hospital | Tampa | Florida | 33606 | — |
| Augusta Oncology Associates - Wheeler Road | Augusta | Georgia | 30909 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| Cancer Care Center of Decatur | Decatur | Illinois | 62526 | — |
| University of Kentucky Chandler Medical Center (UKCMC) | Lexington | Kentucky | 40536 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Barbara Ann Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| START Midwest -Cancer & Hematology Center of Western Michigan | Grand Rapids | Michigan | 49546 | — |
| Regents of the University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Weill Cornell | New York | New York | 10021 | — |
| Mount Sinai | New York | New York | 10029 | — |
| Montefiore Medical Center PRIME | New York | New York | 10461 | — |
| Carolina BioOncology | Huntersville | North Carolina | 28708 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| UC Health, LLC | Cincinnati | Ohio | 45229 | — |
| Case Comprehensive Cancer Center | Cleveland | Ohio | 44106 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Providence Portland Cancer Center | Portland | Oregon | 97213 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Prisma Health | Greenville | South Carolina | 29605 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| Oncology Consultants, P.A. | Houston | Texas | 77024 | — |
| MD Anderson | Houston | Texas | 77030 | — |
| Joe Arrington Cancer Research & Treatment Center | Lubbock | Texas | 79410 | — |
| START Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98331 | — |
| The Board of Regents of the University of Wisconsin | Madison | Wisconsin | 53792 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04669899, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 9, 2024 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04669899 live on ClinicalTrials.gov.